(3-(2-(2,4-difluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone | 1338372-95-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并吡嗪类
• 英文名称: (3-(2-(2,4-difluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone
• 英文别名: [3-[2-(2,4-difluorophenyl)-1,3-thiazol-4-yl]-8-methyl-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-(4-thiophen-2-ylphenyl)methanone
• CAS: 1338372-95-4
• 化学式: C₂₆H₁₉F₂N₅OS₂
• 分子量: 519.599
• InChiKey: ZSIQAOCNFRWDNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  36
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  120
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• [EN] NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS<br/>[FR] NOUVEAUX COMPOSÉS ANTAGONISTES SÉLECTIFS DU RÉCEPTEUR NK-3, COMPOSITION PHARMACEUTIQUE ET MÉTHODES POUR UNE UTILISATION DANS DES TROUBLES À MÉDIATION PAR DES RÉCEPTEURS NK-3
  申请人：EUROSCREEN SA

  公开号：WO2011121137A1

  公开（公告）日：2011-10-06

  The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.

  本发明涉及公式I的新化合物及其作为治疗化合物的用途。
• NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS
  申请人：Euroscreen S.A.

  公开号：US20130023530A1

  公开（公告）日：2013-01-24

  The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.

  本发明涉及一种新型化合物I的使用作为治疗化合物。
• NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
  申请人：Ogeda SA

  公开号：US10065960B2

  公开（公告）日：2018-09-04

  The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.

  本发明涉及式 I 的新型化合物 及其作为治疗化合物的用途。
• NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
  申请人：OGEDA SA

  公开号：US10624890B2

  公开（公告）日：2020-04-21

  Disclosed is use of NK3R antagonists for the therapeutic treatment of pathological excess body fat and/or prevention of body fat gain in patients. Also disclosed is a cosmetic method for stimulating the loss of excess of body fat, including the administration of a NK-3 receptor antagonist.

  本发明公开了 NK3R 拮抗剂在治疗病理性体脂过多和/或预防患者体脂增加方面的用途。还公开了一种刺激减少体内多余脂肪的美容方法，包括施用 NK-3 受体拮抗剂。
• NK-3 RECEPTOR ANTAGONISTS FOR THERAPEUTIC OR COSMETIC TREATMENT OF EXCESS BODY FAT
  申请人：OGEDA SA

  公开号：US20180289705A1

  公开（公告）日：2018-10-11

  Disclosed is use of NK3R antagonists for the therapeutic treatment of pathological excess body fat and/or prevention of body fat gain in patients. Also disclosed is a cosmetic method for stimulating the loss of excess of body fat, including the administration of a NK-3 receptor antagonist.